Clinically, together with the findings from a previous study showing that the CMS4 transcriptome contributes to acquired resistance to anti-EGFR treatment 73, these results indicate that customized targeting of the CMS4 subtype with ICIs may be considered to extend the application of ICIs in CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.